ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1413

Clinical Presentation, Treatment and Outcome of Membranous Nephropathy in SLE: A Comparison with Proliferative Lupus Glomerulonephritis in 141 Patients

Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To study the presentation and outcome of membranous nephropathy in SLE in comparison with proliferative lupus glomerulonephritis.

Methods:

Patients with biopsy firmed active lupus nephritis who were recruited in our randomized comparative trial of mycophenolate mofetil (MMF) vs tacrolimus (Tac) were studied.  Participants were divided into 3 groups: group 1 (pure membranous lupus Gn: RPS/ISN class V); group 2 (mixed membranous and proliferative Gn: class V+III or IVS/IVG) and group 3 (proliferative lupus Gn: IVS/IVG).  The clinical presentation, treatment response, outcome and complications were compared.

Results:

141 patients were studied (92% women; age 35.2±12.8 years; SLE duration 49.3±62 months at renal biopsy). There were 25 patients (18%), 31 patients (22%) and 85 patients (60%) in group 1, 2 and 3, respectively.  At presentation, group 1/2 patients had significantly higher hemoglobin level (11.3±1.8 vs 9.9±1.7g/dL), creatinine clearance (CrCl) (90.0±31 vs 69.7±27ml/min), complement C3 level (0.62±0.27 vs 0.42±0.16g/L) but lower serum Cr (70.8±25 vs 91.5±33umol/L) and anti-dsDNA titer (166±116 vs 234±89IU/ml;p<0.001) than that of group 3 patients (p<0.001 in all). 18 (32%) patients in group 1/2 had normal range C3 or anti-dsDNA, compared to 3 (4%) patients in group 3 (p<0.001). Nephrotic syndrome was more common in group 1/2 than group 3 (46% vs 32%; p=0.08).  Blood pressure and serum albumin level was similar among the 3 groups. SLE disease activity index (SLEDAI) score was significantly lower in group 1/2 than group 3 patients (13.5±4.9 vs 18.0±5.3 points; p<0.001).  Extra-renal activity was less common in group 1/2 than group 3 patients, but the difference was only statistically significant for arthritis (25% vs 42%; p=0.04).  All patients were treated with high-dose prednisolone and either MMF (N=72) or Tac (N=69), followed by low-dose prednisolone and azathioprine for maintenance. Complete response to induction treatment at 6 months, defined as urine P/Cr of <1.0, resolution of active urine sediments, improvement in lupus serology and stabilization of CrCl, was less common with group 1/2 than group 3 patients (45% vs 62%; p=0.10). After a mean of 48.5±21 months, the cumulative risk of loss in 30% of CrCl compared to baseline was 4.6% at year 1, 6.3% at year 3 and 18% at year 5.  Group 1/2 patients did not differ significantly from group 3 patients in terms of decline in CrCl (HR 0.46[0.15-1.46];p=0.19, adjusted for age, sex, SLE duration, initial CrCl and treatment arms).  There were 4 arterial events (2 acute coronary syndrome; 2 cerebrovascular accidents) and 1 venous event (deep vein thrombosis) - all occurred in group 1/2 patients (compared with group 3; p=0.01).  Infections (major and minor) were numerically more common in group 1/2 than group 3 patients.

Conclusion:

The presence of histological membranous component in lupus nephritis is associated with heavier proteinuria, better renal function but less active lupus serology or extra-renal activity such as arthritis. One-third of patients have either normal complements or anti-dsDNA.  Renal function decline in membranous lupus nephropathy is no different from proliferative lupus nephritis at 5 years, but thrombotic complications are more frequent.


Disclosure:

C. C. Mok,
None;

L. Y. Ho,
None;

K. L. Yu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-presentation-treatment-and-outcome-of-membranous-nephropathy-in-sle-a-comparison-with-proliferative-lupus-glomerulonephritis-in-141-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology